More on Forest Laboratories (FRX -5%) FQ3: swings to net loss of $153.6M from profit of $278.4M,...


More on Forest Laboratories (FRX -5%) FQ3: swings to net loss of $153.6M from profit of $278.4M, with earnings hurt by the expiration of Lexapro's patent in March 2012 and upfront licensing payments of $76M. Expects FY 2013 EPS at lower end of forecast of $0.45-$0.60 vs consensus of $0.25 - which looks to be a substantial discrepancy - and revenue of $3.1-$3.2B vs $3.15B. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs